About BGM

BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostic tests based on biomarkers for high-value market opportunities in healthcare that we identify.

We are developing multiple product candidates for cardiac and other diseases and have recently begun limited sales and marketing activities in Europe for our lead product, BGM Galectin-3™. We believe that our tests will provide clinicians with improved information to better detect and characterize disease states. This improved information may enable physicians to achieve better patient outcomes and contain healthcare costs through:

• Earlier diagnosis,
• Segmentation based on underlying disease processes,
• More accurate prognosis, and
• Personalized treatment selection or monitoring of disease based on disease activity.

Our focus is on blood-based tests due to the ease and low cost of access to evaluable samples for testing and the opportunity for repeat sampling to monitor changes in a patient’s medical condition. We are developing our initial product candidates to address significant unmet needs in cardiovascular disease.

* The BGM Galectin-3 test (pending 510(k)) is not available for sale within the United States and is not authorized for sale in Canada.